What is the recommended diagnostic evaluation and treatment approach for cicatricial alopecia?

Cicatricial Alopecia: Diagnostic Evaluation and Treatment

For cicatricial (scarring) alopecia, perform a scalp biopsy in all cases to confirm diagnosis and guide treatment, then initiate anti-inflammatory therapy immediately based on the predominant inflammatory pattern to prevent irreversible follicular destruction. 1, 2

Critical Diagnostic Distinction

Cicatricial alopecia differs fundamentally from alopecia areata—the provided guidelines address alopecia areata (a non-scarring condition), but cicatricial alopecia represents permanent follicular destruction requiring urgent intervention. 3, 2

Diagnostic Evaluation

Clinical Assessment

Perform detailed scalp examination with dermoscopy (trichoscopy) at initial presentation. 1, 3

Key clinical features to identify:

• Absence of follicular ostia (distinguishes scarring from non-scarring alopecia) 3, 2
• Distribution pattern: vertex/central (CCCA), frontal/temporal (frontal fibrosing alopecia), patchy (lichen planopilaris) 4
• Inflammatory signs: erythema, scaling, pustules, or perifollicular erythema 1, 5
• Symptoms: pruritus, burning, tenderness 1

Mandatory Investigations

Scalp biopsy is mandatory in all cases of suspected cicatricial alopecia. 2, 1

Biopsy technique:

• Obtain two 4mm punch biopsies from active disease areas (areas with inflammation, not end-stage scarring) 3, 2
• Submit one for vertical sectioning (H&E) and one for horizontal sectioning 3
• Multiple biopsies may be necessary if initial results are inconclusive due to variable disease course 2

The biopsy determines the inflammatory pattern, which directs treatment:

• Lymphocytic (lichen planopilaris, frontal fibrosing alopecia, CCCA, discoid lupus)
• Neutrophilic (folliculitis decalvans, dissecting cellulitis)
• Mixed pattern 1, 3

Additional Testing When Indicated

• Fungal culture if tinea capitis is in differential 6
• Lupus serology (ANA, anti-dsDNA) if discoid lupus suspected 6, 7
• Consider thyroid function testing, as thyroid disease correlates with worse outcomes in CCCA 5

Treatment Approach

Urgent Treatment Principle

Cicatricial alopecia should be considered a trichologic emergency—initiate treatment immediately after diagnosis to prevent irreversible follicular destruction. 2

First-Line Therapy: Topical and Intralesional Corticosteroids

Begin with high-potency topical corticosteroids (class III-IV) and/or intralesional triamcinolone acetonide injections for most primary cicatricial alopecias. 1, 2

• Intralesional triamcinolone acetonide: 5-10 mg/mL, inject into active areas 1, 7
• This approach applies across most cicatricial alopecia subtypes regardless of inflammatory pattern 1

Systemic Therapy Based on Inflammatory Pattern

For Lymphocytic Cicatricial Alopecias (LPP, FFA, CCCA)

Hydroxychloroquine is the most commonly used first-line systemic agent (200-400 mg daily), though evidence is limited. 8

For lichen planopilaris specifically, methotrexate shows the highest response rate (79.2%) and should be strongly considered. 8

For frontal fibrosing alopecia, retinoids demonstrate the highest response rate (73.9%), though side effects are more common. 8

Alternative systemic options for lymphocytic forms:

• Cyclosporine A shows high efficacy for both LPP and FFA but has higher discontinuation rates due to side effects 8
• Antimalarials (hydroxychloroquine) 7, 2
• Isotretinoin 2

For Neutrophilic Cicatricial Alopecias

Use antibiotics as primary systemic therapy:

• Doxycycline or minocycline (anti-inflammatory doses) 2
• Rifampin combinations for folliculitis decalvans 2
• Add corticosteroids and isotretinoin as needed 2

Central Centrifugal Cicatricial Alopecia (CCCA) Specific Considerations

No established standard of care exists for CCCA, but expert consensus supports:

• Treatment should target inflammation suppression 9
• Patients using metformin (for diabetes), wearing natural hairstyles, and avoiding hooded dryers have significantly better outcomes 5
• Presence of scaling or pustules predicts worse outcomes; these patients require more aggressive therapy 5
• Thyroid disease correlates with worse treatment response; evaluate and optimize thyroid function 5

Treatment Goals and Monitoring

The primary goal is to halt disease progression, not regrow hair in scarred areas—hair regrowth in already scarred regions should not be expected. 1, 3

Monitor for:

• Stabilization of hair loss (50% of patients achieve stability at 1 year) 5
• Reduction in inflammatory signs (erythema, scaling, pustules) 1
• Symptom improvement (pruritus, tenderness) 1

Critical Pitfalls to Avoid

• Delayed diagnosis: Disease progresses subclinically; early intervention is essential 1, 2
• Inadequate biopsy: Single biopsy from end-stage scarred area yields poor diagnostic information 2
• Monotherapy failure: Multiple modality approach often necessary 2
• Ignoring hair care practices: In CCCA, traumatic styling practices perpetuate inflammation 5

Adjunctive Management

Offer psychological support and camouflage techniques to all patients, as permanent hair loss significantly impacts quality of life. 1, 3